Malvern, Pa., February 15, 2012 – Siemens Healthcare has announced that the Food and Drug Administration (FDA) recently cleared the features associated with the new Biograph mCT positron emission tomography/computed tomography (PET•CT) scanner. The new Biograph mCT enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion). Technological innovations and intelligent software solutions within the new PET•CT result in accurate, consistent quantitative assessments. With the new Biograph mCT, which was unveiled last November at the 2011 annual meeting of the Radiological Society of North America (RSNA) in Chicago, Siemens offers yet another paradigm in PET•CT, bolstering the company’s innovative power and competitiveness – a goal of its recently announced global initiative, Agenda 2013.
Accuracy and reproducibility in PET quantification enable the physician to more precisely characterize cancer lesions, which permits better staging and monitoring of changes in activity over time for more accurate assessment of treatment response. The ability to measure absolute myocardial blood flow in cardiology allows the physician to more accurately assess multi-vessel disease. In neurology, noninvasive assessment of the brain can potentially improve the diagnosis and management of patients who present with signs of dementia.
source: Siemens Medical